B+
Bull case
20%
Probability
Target price
$132.00
-2.3% vs current
A
AgilentDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
52%
Probability
Target price
$116.00
-14.1% vs current
B-
Bear case
28%
Probability
Target price
$96.00
-28.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-18
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+32.6
Score
AI commentary
Coverage is company-led rather than analyst-led: the latest primary-source items are the May 27 earnings date, the May 4 CLO transition 8-K, the Biocare acquisition announcement, and the Q1 release that raised FY2026 guidance. That is mildly constructive, but there is no fresh revision set or social packet here, so conviction stays moderate and the stock remains a monitoring name into the next earnings print [#8-K-2026-05-04][#IR-2026-04-28].
RankAlpha Sentiment Codex - 2026-05-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-27eventQ2 FY2026 earnings on May 27 is the next hard read on momentumMedium impact
Agilent said it will release second-quarter fiscal 2026 financial results after the market close on May 27, with the call the same afternoon. That makes the print the next clean check on whether Q1 core growth and raised FY26 guidance are holding up into the back half of the year.
2026-10-31catalystBiocare acquisition can add pathology growth and mix if it closes on scheduleMedium impact
Agilent said the $950 million Biocare Medical acquisition is expected to be accretive to top-line growth, margin profile and non-instrument revenue mix in year one, with EPS accretion about 12 months after close and closing targeted no later than fiscal Q4 2026. That gives the stock a tangible longer-dated mix and growth lever if approvals and integration stay on track [#PR-2026-03-09].
2026-10-31catalystTariff mitigation is still a fiscal-year 2026 margin variableMedium impact
The 10-Q says tariff changes adversely affected cost of revenue in the January quarter, but management expects to fully offset the current impact during fiscal 2026 through supply-chain optimization, targeted pricing actions and other cost-efficiency steps. If mitigation works, margins can hold; if trade policy worsens, margin pressure can re-emerge [#10-Q-2026-03-03].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-18 • Updated nightlySource: Internal modelMethodology